Champions Oncology, Inc. key statistics and ratios

In fiscal 2026, Champions Oncology, Inc. had return on equity of -30.5%, an operating margin of -1.9%, debt equal to 0.0% of equity and a current ratio of 0.96. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Champions Oncology, Inc.: financial ratios, annual
Fiscal year	2018Apr 2018	2019Apr 2019	2020Apr 2020	2021Apr 2021	2022Apr 2022	2023Apr 2023	2024Apr 2024	2025Apr 2025	2026Apr 2026	LTMJul 2026
Gross margin	—	—	47.1%	47.7%	51.9%	45.2%	41.4%	50.1%	48.0%	49.8%
Operating margin	−6.7%	1.0%	−6.0%	0.9%	1.2%	−9.8%	−14.7%	8.0%	−1.9%	−1.7%
Net margin	−7.3%	0.5%	−6.5%	0.9%	1.1%	−9.9%	−14.5%	8.3%	−2.0%	−1.8%
Free-cash-flow margin	−12.1%	3.8%	2.1%	−12.1%	8.4%	2.0%	−13.9%	12.3%	−8.5%	−10.1%
Return on equity	—	12.0%	−57.8%	5.8%	6.6%	−77.7%	—	—	−30.5%	−28.2%
Return on assets	−18.3%	1.3%	−13.1%	1.5%	1.7%	−15.3%	−24.1%	16.1%	−4.0%	−3.7%
Asset turnover	2.51	2.80	2.01	1.70	1.56	1.55	1.66	1.95	2.00	2.01
Current ratio	0.68	0.99	1.10	1.13	1.13	0.90	0.63	0.94	0.96	1.03
Debt to equity	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	0.0%	0.0%	0.0%
Effective tax rate	—	44.6%	—	17.2%	6.0%	—	—	−1.6%	—	—
R&D as % of revenue	21.7%	17.7%	18.2%	17.5%	19.1%	21.4%	19.0%	12.0%	15.3%	15.4%
Capital spending as % of revenue	6.1%	3.1%	6.9%	8.0%	4.9%	5.3%	1.7%	0.7%	0.9%	0.9%
Free cash flow ÷ net income	—	803.1%	—	<−999%	750.5%	—	—	148.8%	—	—
Dividends and buybacks ÷ free cash flow	—	—	—	—	0.0%	6.7%	—	0.0%	—	—

US$ thousands unless shown otherwise. Fiscal quarters.

Champions Oncology, Inc.: financial ratios, quarterly
Quarter	2025 Q2Oct 2024	2025 Q3Jan 2025	2025 Q4Apr 2025	2026 Q1Jul 2025	2026 Q2Oct 2025	2026 Q3Jan 2026	2026 Q4Apr 2026	2027 Q1Jul 2026
Gross margin	44.9%	61.2%	41.1%	42.9%	51.7%	46.7%	50.8%	50.5%
Operating margin	5.4%	26.4%	−16.2%	−3.8%	1.2%	−1.7%	−3.8%	−2.7%
Net margin	5.4%	26.4%	−14.9%	−3.3%	1.8%	−1.7%	−4.8%	−2.8%
Free-cash-flow margin	−2.8%	2.6%	53.5%	4.0%	−13.1%	−8.3%	−16.2%	−3.6%
Current ratio	0.75	0.99	0.94	0.93	0.96	0.98	0.96	1.03
R&D as % of revenue	12.5%	10.1%	15.9%	14.9%	17.4%	13.7%	15.3%	15.4%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · July 31, 2026

What it owns · $33m

Short-term assets $19mLonger-term assets $14m

What it owes, and who funded it · $33m

Short-term liabilities $19mLonger-term liabilities $10mShareholders' equity $4m

Short-term assets cover short-term liabilities $19m of assets due within a year against $19m of liabilities due within a year.
Short-term assets cover long-term liabilities $19m short-term assets against $10m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Champions Oncology, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

63 /100

Moderate moat

How hard Champions Oncology's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 20 / 20

Cash operating profit has been a median 28.6% of total assets over 7 years.
Pricing power 16 / 20

Gross margin has been a median 48.5%, moving by 2.8 percentage points (standard deviation) across 7 years.
Durability 10 / 20

Operating margin has been a median -1.7%; its worst year was -14.3%.
Cash conversion 4 / 20

Free cash flow was positive in 4 of 9 years, at a median -0.5% of revenue.
Discipline 18 / 20

The diluted share count fell 3.5% over five years; stock-based pay has been a median 1.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (68 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: CSBR vs PRPO CSBR vs MASS CSBR vs PSNL

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Champions Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Champions Oncology, Inc.